oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Epigenetic changes as prognostic predictors in endometrial carcinomas
Örebro University, School of Health Sciences. Orebro University Hospital. Department of Laboratory Medicine.
Örebro University, School of Health Sciences. Orebro University Hospital. Department of Oncology.ORCID iD: 0000-0002-5063-631X
Department of Medical Biosciences/Clinical Chemistry, Umeå University, Umeå, Sweden.
2017 (English)In: Epigenetics, ISSN 1559-2294, E-ISSN 1559-2308, Vol. 12, no 1, 19-26 p.Article in journal (Refereed) Published
Abstract [en]

Endometrial carcinoma is one of the most frequent gynecological malignancies of the female. The diagnostic and prognostic markers for the high-risk subgroups with unfavorable prognosis are under intense debate worldwide, and, therefore, the aim of this study was to identify new potential DNA methylation markers for the high-risk groups. We used the Illumina Infinium HumanMethylation450 BeadChip to analyze the DNA methylation pattern and investigated its association with clinicopathological features important for defining the high-risk (FIGO-grade 3) and low-risk (FIGO-grade 1) groups of patients with endometrial cancer (n = 31 and n = 39, respectively). We identified specific DNA methylation signature in high-risk endometrial tumors, and potential molecular biomarker genes (TBX2, CHST11, and NID2) associated with unfavorable clinical predictive and prognostic factors.

Place, publisher, year, edition, pages
Taylor & Francis, 2017. Vol. 12, no 1, 19-26 p.
Keyword [en]
DNA methylation; endometrial cancer; FIGO grade; prognosis
National Category
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy) Genetics
Identifiers
URN: urn:nbn:se:oru:diva-53666DOI: 10.1080/15592294.2016.1252891ISI: 000394449200003PubMedID: 27874289ScopusID: 2-s2.0-85007417723OAI: oai:DiVA.org:oru-53666DiVA: diva2:1050129
Funder
Swedish Research Council
Note

Funding Agencies:

Lions Cancer Foundation, Uppsala

Nyckelfonden, Örebro

Cancer-forskningsfonden, Umeå

Available from: 2016-11-28 Created: 2016-11-28 Last updated: 2017-04-04Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Farkas, Sanja A.Sorbe, Bengt G.
By organisation
School of Health SciencesOrebro University Hospital
In the same journal
Epigenetics
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)Genetics

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 23 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf